Cary Pfeffer Net Worth

Cary Pfeffer biography

Dr. Cary G. Pfeffer M.D. serves as Independent Director of the Company. Dr. Pfeffer is a partner at TRV, which he joined in 2007. Dr. Pfeffer served as the chairman of our board from July 2014 to April 2016 and as our interim chief executive officer from February 2013 to July 2014. Dr. Pfeffer was the interim chief executive officer of Neon Therapeutics, Inc., a public immuno-oncology company, from October 2015 to September 2016, the interim chief business officer of Rheos Medicines, Inc., a private biotechnology company, from March 2018 to November 2018, and the interim chief business officer of Casma Therapeutics, Inc., a private biotechnology company, from May 2018 to December 2018. Dr. Pfeffer has served as a director of Neon Therapeutics, Inc. since May 2015 and is currently the chairman of the board; he also serves on the boards of directors for several private companies, including Casma Therapeutics, Inc., Rheos Medicines, Inc. and Tango Therapeutics, Inc. From August 2009 to September 2016, Dr. Pfeffer was a member of the board of directors of Eleven Biotherapeutics, Inc., a public biologics oncology company, and served as its chief business officer from February 2010 to September 2011. Dr. Pfeffer received an M.B.A. from the Wharton School of Business, an M.D. from the University of Pennsylvania School of Medicine and a B.A. in biochemistry from Columbia University.

What is the salary of Cary Pfeffer?

As the Independent Director of Jounce Therapeutics Inc, the total compensation of Cary Pfeffer at Jounce Therapeutics Inc is $86,304. There are 12 executives at Jounce Therapeutics Inc getting paid more, with Kimberlee Drapkin having the highest compensation of $2,032,250.

What's Cary Pfeffer's mailing address?

Cary's mailing address filed with the SEC is C/O THIRD ROCK VENTURES, LLC,, 29 NEWBURY STREET, 3RD FLOOR, BOSTON, MA, 02116.

Insiders trading at Jounce Therapeutics Inc

Over the last 8 years, insiders at Jounce Therapeutics Inc have traded over $39,574,093 worth of Jounce Therapeutics Inc stock and bought 724,587 units worth $10,288,083 . The most active insiders traders include Kevin Ctang Capital Managem..., Harbor Master Investors (Ca... e Rock Ventures Ii, L.P.Third.... On average, Jounce Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $171,610. The most recent stock trade was executed by Richard /Ca/ Murray on 4 April 2023, trading 39,228 units of JNCE stock currently worth $72,572.

What does Jounce Therapeutics Inc do?

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce's internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce's broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc.

Jounce Therapeutics Inc executives and stock owners

Jounce Therapeutics Inc executives and other stock owners filed with the SEC include:

• Kimberlee Drapkin,
  Chief Financial Officer, Treasurer
• Richard Murray,
  President, Chief Executive Officer, Director
• Dr. Richard Murray,
  Pres, CEO & Director
• Hugh Cole,
  Chief Business Officer, Head of Corporate Development
• Elizabeth Trehu,
  Chief Medical Officer
• Hugh M. Cole,
  Chief Bus. Officer & Head of Corp. Devel.
• Kimberlee Cobleigh Drapkin CPA, CPA,
  CFO & Treasurer
• Dr. Elizabeth G. Trehu,
  Chief Medical Officer
• Perry Karsen,
  Independent Chairman of the Board
• Barbara Duncan,
  Independent Director
• J. Duncan Higgons,
  Independent Director
• Luis Diaz,
  Independent Director
• Cary Pfeffer,
  Independent Director
• Robert Tepper,
  Independent Director
• Robert Kamen,
  Independent Director
• Robert Iannone,
  Independent Director
• Dr. Stephen G. Farrand Ph.D.,
  Chief Technical Officer
• Dr. Louis M. Weiner M.D.,
  Founder
• Dr. Padmanee Sharma M.D., Ph.D.,
  Founder
• Dr. Thomas F. Gajewski M.D., Ph.D.,
  Founder
• Dr. Louis M. Weiner,
  Founder
• Dr. Padmanee Sharma,
  Founder
• Dr. Drew Mark Pardoll M.D., Ph.D.,
  Founder
• Dr. Robert D. Schreiber,
  Founder
• Dr. Thomas F. Gajewski,
  Founder
• Dr. James P. Allison,
  Founder
• Switzerland Llccelgene Corp...,
  
• Rock Ventures Ii, L.P.Third...,
  
• Harbor Master Investors (Ca...,
  10% owner
• Biosciences, Llc Concentra,
  10% owner
• Luisa Salter Cid,
  Director
• Rock Ventures Ii, L.P.Third...,
  
• Kevin Ctang Capital Managem...,
  
• Jigar Raythatha,
  Director
• Rock Ventures Iii, L.P.Thir...,